A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
A phase II study of irinotecan in 3 line or more therapy in local recurrence or metastatic
breast cancer. Evaluate the effect and safety of irinotecan in local recurrence or Metastatic
breast cancer patients who recieved anthracycline or taxane drugs. The primary endpoint is
Disease Control Rate and Progression free survival. The second endpoint is 3 or 4 grade
Adverse Events 、overall survival.All the patients will recieve this therapy till disease
progress or other occurrence of withdrawal standards.